Bolt Biotherapeutics - BOLT Stock Forecast, Price & News

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Bolt Biotherapeutics in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BOLT shares.
View BOLT analyst ratings or view top-rated stocks.

4 analysts have issued 12 month target prices for Bolt Biotherapeutics' shares. Their BOLT share price forecasts range from $4.00 to $45.00. On average, they predict the company's stock price to reach $16.75 in the next twelve months. This suggests a possible upside of 873.8% from the stock's current price.
View analysts price targets for BOLT or view top-rated stocks among Wall Street analysts.

Bolt Biotherapeutics' stock was trading at $4.90 at the start of the year. Since then, BOLT stock has decreased by 64.9% and is now trading at $1.72.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 8th 2022.
View our BOLT earnings forecast.

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) announced its quarterly earnings data on Monday, November, 8th. The company reported ($0.63) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.75) by $0.12. The firm had revenue of $0.75 million for the quarter, compared to analysts' expectations of $1.50 million. Bolt Biotherapeutics had a negative net margin of 2,795.56% and a negative trailing twelve-month return on equity of 40.31%.

Based on aggregate information from My MarketBeat watchlists, some companies that other Bolt Biotherapeutics investors own include Allena Pharmaceuticals (ALNA), Ampliphi Biosciences (APHB), Arbutus Biopharma (ABUS), Aurora Cannabis (ACBFF), AcelRx Pharmaceuticals (ACRX), Aldeyra Therapeutics (ALDX), Ampio Pharmaceuticals (AMPE), Apellis Pharmaceuticals (APLS), Aquantia (AQ) and Aquinox Pharmaceuticals (AQXP).

(BOLT) raised $150 million in an initial public offering on Friday, February 5th 2021. The company issued 8,800,000 shares at $16.00-$18.00 per share. Morgan Stanley, SVB Leerink, Stifel and Guggenheim Securities acted as the underwriters for the IPO.

Bolt Biotherapeutics trades on the NASDAQ under the ticker symbol "BOLT."

Bolt Biotherapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (1.44%), Assenagon Asset Management S.A. (0.74%), Millennium Management LLC (0.51%), Russell Investments Group Ltd. (0.26%), Marquette Asset Management LLC (0.17%) and State Street Corp (0.13%). Insiders that own company stock include Edgar Engleman, Holdings A/S Novo, Randall C Schatzman, Vivo Capital Fund Viii, LP and William P Quinn.
View institutional ownership trends.

Shares of BOLT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BOLT stock can currently be purchased for approximately $1.72.

Bolt Biotherapeutics (NASDAQ:BOLT) has a market capitalization of $64.74 million and generates $1.26 million in revenue each year. The company earns $-98,590,000.00 in net income (profit) each year or ($2.61) on an earnings per share basis.

Bolt Biotherapeutics' mailing address is 900 CHESAPEAKE DRIVE, REDWOOD CITY CA, 94063. The official website for the company is www.boltbio.com. The company can be reached via phone at 650-665-9295 or via email at sarah.mccabe@sternir.com.